Yuan P, et al. - Researchers compared the efficacy and safety of eribulin monotherapy with vinorelbine in Chinese women with locally recurrent/metastatic breast cancer (MBC) enrolled in this phase 3, open-label, randomized, parallel-group, multicenter trial. These patients had had 2–5 prior chemotherapy regimens, including an anthracycline and taxane. In a randomized 1:1 manner, 264 patients received eribulin (1.4 mg/m² intravenously on days 1 and 8) and 266 received vinorelbine (25 mg/m² intravenously on days 1, 8, and 15) every 21 days. In this population, statistically significantly superior progression-free survival and response rates were achieved with eribulin vs vinorelbine. Participants better tolerated eribulin than vinorelbine, with no new safety signals observed.